The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Updates from the MURANO trial
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, gives an update on the MURANO study (NCT02005471). MURANO was the first study to investigate fixed-duration venetoclax plus rituximab compared with bendamustine and rituximab in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Prof. Kater notes that many publications and presentations have come from this study – including a deep dive into measurable residual disease (MRD) and its use as a surrogate endpoint, as well as reports on mechanisms of resistance and re-treating patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
